EssilorLuxottica Gets FDA Approval for Lens to Slow Myopia Progression

Dow Jones

09/26

By Kelly Cloonan

EssilorLuxottica has received market authorization from the Food and Drug Administration for a lens that aims to slow myopia progression in children.

The Ray-Ban owner said Thursday it now plans to make its Essilor Stellest lens available in the coming weeks for U.S. eyecare professionals. It has already launched the lens internationally.

The lens marks the first FDA market authorized spectacle lens clinically proven to slow myopia progression in children, the company said.

Myopia impacts millions, with half the world population expected to suffer from myopia by 2050, the company said. Higher levels of myopia are frequently associated with severe eye pathologies later in life.

Clinical data show the Essilor Stellest lens slowed myopia progression in children aged six to 12 years by an average of 71% over two years, compared to single vision lenses, the company said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

September 25, 2025 18:05 ET (22:05 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2570404249"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2570404249\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2570404249?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-26 06:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2570404249","market":"hk","top_or_hot":-1,"title":"EssilorLuxottica Gets FDA Approval for Lens to Slow Myopia Progression","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ESLOF\">EssilorLuxottica</a> has received market authorization from the Food and Drug Administration for a lens that aims to slow myopia progression in children. \n</p>\n<p>\n  The Ray-Ban owner said Thursday it now plans to make its Essilor Stellest lens available in the coming weeks for U.S. eyecare professionals. It has already launched the lens internationally. \n</p>\n<p>\n  The lens marks the first FDA market authorized spectacle lens clinically proven to slow myopia progression in children, the company said. \n</p>\n<p>\n  Myopia impacts millions, with half the world population expected to suffer from myopia by 2050, the company said. Higher levels of myopia are frequently associated with severe eye pathologies later in life. \n</p>\n<p>\n  Clinical data show the Essilor Stellest lens slowed myopia progression in children aged six to 12 years by an average of 71% over two years, compared to single vision lenses, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 25, 2025 18:05 ET (22:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EssilorLuxottica Gets FDA Approval for Lens to Slow Myopia Progression</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEssilorLuxottica Gets FDA Approval for Lens to Slow Myopia Progression\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-09-26 06:05</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ESLOF\">EssilorLuxottica</a> has received market authorization from the Food and Drug Administration for a lens that aims to slow myopia progression in children. \n</p>\n<p>\n  The Ray-Ban owner said Thursday it now plans to make its Essilor Stellest lens available in the coming weeks for U.S. eyecare professionals. It has already launched the lens internationally. \n</p>\n<p>\n  The lens marks the first FDA market authorized spectacle lens clinically proven to slow myopia progression in children, the company said. \n</p>\n<p>\n  Myopia impacts millions, with half the world population expected to suffer from myopia by 2050, the company said. Higher levels of myopia are frequently associated with severe eye pathologies later in life. \n</p>\n<p>\n  Clinical data show the Essilor Stellest lens slowed myopia progression in children aged six to 12 years by an average of 71% over two years, compared to single vision lenses, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 25, 2025 18:05 ET (22:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ESLOY","symbol_name":"EssilorLuxottica","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2570404249","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2570404249","pubTimestamp":1758837900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"EssilorLuxottica has received market authorization from the Food and Drug Administration for a lens that aims to slow myopia progression in children.The Ray-Ban owner said Thursday it now plans to make its Essilor Stellest lens available in the coming weeks for U.S. eyecare professionals. It has already launched the lens internationally.The lens marks the first FDA market authorized spectacle lens clinically proven to slow myopia progression in children, the company said.Myopia impacts millions, with half the world population expected to suffer from myopia by 2050, the company said. Higher levels of myopia are frequently associated with severe eye pathologies later in life.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ESLOY":"EssilorLuxottica","BK4198":"医疗保健用品","BK4202":"服装、服饰与奢侈品","06613":"蓝思科技","BK1170":"电子元件"},"translate_title":"EssilorLuxottica获得FDA批准用于减缓近视进展的镜片","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06613":1.5,"ESLOY":0.9},"content_text":"By Kelly Cloonan \n\n\n \n\n\nEssilorLuxottica has received market authorization from the Food and Drug Administration for a lens that aims to slow myopia progression in children. \n\n\n  The Ray-Ban owner said Thursday it now plans to make its Essilor Stellest lens available in the coming weeks for U.S. eyecare professionals. It has already launched the lens internationally. \n\n\n  The lens marks the first FDA market authorized spectacle lens clinically proven to slow myopia progression in children, the company said. \n\n\n  Myopia impacts millions, with half the world population expected to suffer from myopia by 2050, the company said. Higher levels of myopia are frequently associated with severe eye pathologies later in life. \n\n\n  Clinical data show the Essilor Stellest lens slowed myopia progression in children aged six to 12 years by an average of 71% over two years, compared to single vision lenses, the company said. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 25, 2025 18:05 ET (22:05 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}